Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Decentralized Phase II Randomized Controlled Trial of Atorvastatin in Resected High-Risk Melanoma

NCT06157099 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT06157099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06157099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Decentralized Phase II Randomized Controlled Trial of Atorvastatin in Resected High-Risk Melanoma
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 1, 2024
Completion date
September 1, 2029
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pathologic stage iia cutaneous melanoma ajcc v8, pathologic stage iib cutaneous melanoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8